HEBER NASVAC-vaccine for the treatment of hepatitis B

HEBER NASVAC - Cuban therapeutic vaccine for the treatment of HEPATITIS B, MANUFACTURED BY CIGB (CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY) HAVANA, CUBA                    

 At the end of 2015, the first therapeutic vaccine for the treatment of chronic hepatitis B, Heber Nasvac, created by Cuban scientists at the Center for Genetic Engineering and Biotechnology (CIGB), was certified in Cuba. Clinical trials were carried out jointly with the French company ABIVAX over several years in 50 clinical centers around the world.

    Features and advantages of the Cuban vaccine

1. The vaccine is available as a nasal spray or as a solution for subcutaneous administration;
2. The therapeutic vaccine consists of 2 recombinant proteins of the hepatitis B virus (HBV): surface antigen (HBsAg) and nucleocapsid (core) antigen (HBcAg);
3. The effect of the vaccine is similar to that of PEG-interferon alpha - 2a (PEG - IFN 2 alpha;), but the vaccine has demonstrated a unique sustainable effect, which is achieved by a shorter duration of administration and better tolerability of the drug;
4. The use of a therapeutic vaccine allows patients to overcome the immune paralysis that is characteristic of the chronic form of hepatitis B;
5. The use of the Heber Nasvac vaccine will allow some patients to be cured of hepatitis B, and will enable many patients who require daily, lifelong therapy to manage this devastating disease.